Guy Cantin

539 total citations
23 papers, 276 citations indexed

About

Guy Cantin is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Guy Cantin has authored 23 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Oncology and 6 papers in Genetics. Recurrent topics in Guy Cantin's work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Guy Cantin is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Guy Cantin collaborates with scholars based in Canada, France and United States. Guy Cantin's co-authors include C. Demers, Jean Roy, Robert Delage, James K. Brennan, Pierre Leblond, Morel Rubinger, Catherine Doyle, Félix Couture, Robert Sutherland and Louise Provencher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Guy Cantin

22 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guy Cantin Canada 9 159 97 79 56 48 23 276
Laura Gallur Spain 6 184 1.2× 55 0.6× 69 0.9× 83 1.5× 38 0.8× 18 266
R. Erttmann Germany 9 190 1.2× 112 1.2× 32 0.4× 46 0.8× 58 1.2× 16 344
H. L. Seewann Austria 11 208 1.3× 102 1.1× 109 1.4× 57 1.0× 33 0.7× 27 325
C Stainer United Kingdom 11 282 1.8× 122 1.3× 84 1.1× 75 1.3× 90 1.9× 12 384
Silvia Trappolini Italy 7 154 1.0× 48 0.5× 42 0.5× 79 1.4× 96 2.0× 13 290
Francisco Javier Peñalver Spain 6 136 0.9× 47 0.5× 139 1.8× 130 2.3× 31 0.6× 13 310
Ozan Salim Türkiye 11 84 0.5× 52 0.5× 65 0.8× 42 0.8× 49 1.0× 46 271
Laurent Pascal France 9 272 1.7× 136 1.4× 195 2.5× 83 1.5× 41 0.9× 25 438
U. Wandl Germany 10 250 1.6× 72 0.7× 161 2.0× 48 0.9× 42 0.9× 26 343
Marzia Defina Italy 10 271 1.7× 61 0.6× 113 1.4× 83 1.5× 74 1.5× 35 355

Countries citing papers authored by Guy Cantin

Since Specialization
Citations

This map shows the geographic impact of Guy Cantin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Cantin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Cantin more than expected).

Fields of papers citing papers by Guy Cantin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Cantin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Cantin. The network helps show where Guy Cantin may publish in the future.

Co-authorship network of co-authors of Guy Cantin

This figure shows the co-authorship network connecting the top 25 collaborators of Guy Cantin. A scholar is included among the top collaborators of Guy Cantin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guy Cantin. Guy Cantin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deschênes‐Simard, Xavier, Frédéric Barabé, Vinçent Laroche, et al.. (2024). Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study. Leukemia & lymphoma. 65(13). 1974–1982. 2 indexed citations
2.
Leblanc, Dominique, Guy Cantin, Alexandra Desnoyers, et al.. (2023). Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion. Current Oncology. 30(2). 1416–1425. 3 indexed citations
3.
Barabé, Frédéric, Vinçent Laroche, Geneviève Gallagher, et al.. (2022). Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study. Blood. 140(Supplement 1). 3304–3305. 1 indexed citations
4.
Berg, Tobias, Jonathan L. Bramson, Christopher Bredeson, et al.. (2022). Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference. Current Oncology. 29(12). 9970–10017.
5.
Bosch, Francesc, Guy Cantin, Agostino Cortelezzi, et al.. (2019). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 34(2). 441–450. 6 indexed citations
6.
Paulson, Kristjan, John Kuruvilla, Christopher Bredeson, et al.. (2016). Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. Biology of Blood and Marrow Transplantation. 22(3). S37–S38. 2 indexed citations
7.
Lemieux, Julie, Geneviève Forget, Louise Provencher, et al.. (2014). Evaluation of eligibility and recruitment in breast cancer clinical trials. The Breast. 23(4). 385–392. 5 indexed citations
8.
Côté, Julie Anne, Guy Cantin, Julie Lemieux, & Geneviève Gallagher. (2014). Allogeneic stem cell transplantation (SCT) using a CAT-bu conditioning regimen in patients with advanced myelodysplastic/myeloproliferative disorders (MDS-MPDs).. Journal of Clinical Oncology. 32(15_suppl). 7035–7035. 1 indexed citations
9.
Poirier, Éric, Christine Desbiens, Brigitte Poirier, et al.. (2013). Comparison of Serious Adverse Events Between the Original and a Generic Docetaxel in Breast Cancer Patients. Annals of Pharmacotherapy. 48(4). 447–455. 10 indexed citations
10.
Carde, Patrice, Matthias Karrasch, Catherine Fortpied, et al.. (2012). ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup  randomized phase III clinical trial.. Journal of Clinical Oncology. 30(15_suppl). 8002–8002. 25 indexed citations
11.
Sehn, Laurie H., David MacDonald, S. Rubin, et al.. (2009). Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.. Blood. 114(22). 407–407. 4 indexed citations
12.
Lemieux, Julie, Geneviève Forget, Stéphanie Camden, et al.. (2009). Evaluation of Factors Associated with Recruitment in Breast Cancer Clinical Trials in a Specialized Breast Cancer Centre.. Cancer Research. 69(24_Supplement). 5122–5122. 1 indexed citations
13.
Walker, Irwin, Nadine Shehata, Guy Cantin, et al.. (2004). Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Molecules and Diseases. 33(3). 222–226. 19 indexed citations
14.
Walker, I., Guy Cantin, Félix Couture, et al.. (2004). Canadian pilot trial of haplo-identical donor transplantation. Biology of Blood and Marrow Transplantation. 10. 38–38. 1 indexed citations
15.
Roy, Jean, et al.. (1999). A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplantation. 23(10). 991–996. 50 indexed citations
16.
Delage, Robert, C. Demers, Guy Cantin, & Jean Roy. (1996). Treatment of essential thrombocythemia during pregnancy with interferon-alpha.. PubMed. 87(5 Pt 2). 814–7. 39 indexed citations
17.
18.
Cantin, Guy, et al.. (1989). Blood-derived stem cell collection in acute nonlymphoblastic leukemia: predictive factors for a good yield.. PubMed. 17(10). 991–6. 23 indexed citations
19.
Cantin, Guy & James K. Brennan. (1984). High‐dose cytosine arabinoside for acute nonlymphocytic leukemia. American Journal of Hematology. 16(1). 59–66. 20 indexed citations
20.
Cantin, Guy, et al.. (1983). Anti‐PP1Pk and early abortion. Transfusion. 23(4). 350–351. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Gallur Breakdown of academic impact, for papers by R. Erttmann Breakdown of academic impact, for papers by H. L. Seewann Breakdown of academic impact, for papers by C Stainer Breakdown of academic impact, for papers by Silvia Trappolini Breakdown of academic impact, for papers by Francisco Javier Peñalver Breakdown of academic impact, for papers by Ozan Salim Breakdown of academic impact, for papers by Laurent Pascal Breakdown of academic impact, for papers by U. Wandl Breakdown of academic impact, for papers by Marzia Defina
Rankless by CCL
2026